Pfizer began recalling its thyroid drug Levoxyl this year after getting complaints of odors from the bottles tied to a new formulation, a move that threatened to lead to a shortage of the drug. So its King Pharmaceuticals subsidiary returned to making the older formulation. But now it has to recall 84 lots of that product because there appears to be potency issues.
China has often been maligned in Africa as the source of counterfeit drugs, a reputation that the government is not at all happy about. Chinese authorities this year even took the unusual step of defending their country against a report in a U.K. newspaper that it was a primary source of fake antimalarial drugs in Uganda and Tanzania.
Forty-five women are seeking $800 million (U.S. $778.8 million) in a class-action lawsuit filed Friday, claiming a packaging foul-up by Apotex led them to take placebos instead of the active birth control pills.
China's Biostar had to stop production and destroy about 5 million capsules after it learned last year that the supply had been contaminated with chromium. The capsule scandal also turned out to be toxic to its earnings.
India may be closer to implementing a track and trace system for drug distribution than the U.S. is.
Smelly pills have led to another recall by Pfizer and this time a drug shortage. Last year Pfizer recalled more than 650,000 bottles of Advil gel tabs from stores because they had a strong odor. This time it is Pfizer subsidiary King Pharmaceuticals recalling 52,000 bottles of its thyroid pill Levoxyl because of a bad odor.
Frazier Healthcare, the Seattle-based investment firm, sees opportunity in drug packaging. For the second time in 11 months, it has put together a deal to buy a pharmaceutical packaging operation, this time picking up the largest contract operator in the U.S.
Drugs being pulled off of shelves because of bad odors is not a rarity. This time, it involves nearly 600,000 bottles of Glenmark Pharmaceuticals' generic version of the Merck blockbuster asthma med, Singulair.
A recall of four batches of a Teva Pharmaceutical Industries ($TEVA) generic drug has been updated in the U.K. because the original recall got batch numbers wrong.
Takeda Pharmaceutical and one of its contract manufacturers have run afoul of authorities in Japan, leading to the temporary closure of a manufacturing plant.